ELAN logo

ELANCO ANIMAL HEALTH INC

ELANNYSE
πŸ† #818 by market capEarnings Nov 6US Equity
$22.62β–² $0.17 (+0.76%)
After hours Β· at close
πŸ””
Track ELAN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.8%
7dβ–Ό 1.4%
14dβ–Ό 1.7%
30dβ–Ό 6.2%
ytdβ–Ό 0.1%
1yβ–² 15.3%
🏦Market Cap
$11.30B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+6.2%
Slowing
πŸ“ŠGross Margin
52.6%
Healthy
πŸ’΅FCF Margin
7.5%
Moderate
βš–οΈP/S Ratio
2.2x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$22.47 – $22.88
52-Week Range
$19.40 – $27.98
Volume
$3.18B
Avg Volume
$2.44B
Shares Outstanding
499.4M
Next Earnings
Nov 20, 2026

Fundamentals Snapshot

Annual Revenue
$4.71B
Last Q Revenue
$1.37B
P/E Ratio
-55.1
P/S Ratio
2.2x
EPS (TTM)
$-0.40
Dividend Yield
0.00%
Dilution (1yr)
+0.5%

Why Investors Own ELAN

  • βœ“High-growth profile β€” revenue up +12.3% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 36% gross margin and 12% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ELAN logo

ELANCO ANIMAL HEALTH INC

ELAN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4.7Bβ–² +6.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
43.5%β–² +1.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$252Mβ–² +0.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$284Mβ–Ό βˆ’27.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
496.9Mβ–² +0.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$3.5Bβ–² +$381M YoY
StockOtter Β· stockotter.space

About ELANCO ANIMAL HEALTH INC

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
23 analysts
Strong Buy10
Buy11
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates